Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Mimedx (MDXG) over the last 15 years, with Q3 2025 value amounting to $3.0 million.

  • Mimedx's Other Non-Current Assets rose 15313.56% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 15313.56%. This contributed to the annual value of $1.1 million for FY2024, which is 43951.22% up from last year.
  • Latest data reveals that Mimedx reported Other Non-Current Assets of $3.0 million as of Q3 2025, which was up 15313.56% from $990000.0 recorded in Q2 2025.
  • In the past 5 years, Mimedx's Other Non-Current Assets registered a high of $3.0 million during Q3 2025, and its lowest value of $146000.0 during Q2 2023.
  • Moreover, its 5-year median value for Other Non-Current Assets was $313000.0 (2021), whereas its average is $732263.2.
  • Per our database at Business Quant, Mimedx's Other Non-Current Assets skyrocketed by 90322.58% in 2022 and then plummeted by 8901.39% in 2023.
  • Mimedx's Other Non-Current Assets (Quarter) stood at $186000.0 in 2021, then surged by 903.23% to $1.9 million in 2022, then plummeted by 89.01% to $205000.0 in 2023, then skyrocketed by 439.51% to $1.1 million in 2024, then surged by 170.07% to $3.0 million in 2025.
  • Its Other Non-Current Assets stands at $3.0 million for Q3 2025, versus $990000.0 for Q2 2025 and $1.0 million for Q1 2025.